Improving outcomes of AF ablation by integrated personalized lifestyle interventions: rationale and design of the prevention to improve outcomes of PVI (POP) trial
Open Access
- 31 March 2023
- journal article
- research article
- Published by Springer Nature in Clinical Research in Cardiology
- Vol. 112 (6) , 716-723
Abstract
Progression of atrial fibrillation (AF) and outcomes of ablation therapy are strongly affected by modifiable risk factors. Although previous studies show beneficial effects of modifying single risk factors, there is lack of evidence from randomized controlled trials on the effects of integrated AF lifestyle programmes. The POP trial is designed to evaluate the clinical outcomes of a dedicated nurse-led AF lifestyle outpatient clinic in patients with symptomatic AF. This study is a prospective, 1:1 randomized, single centre, investigator-initiated clinical trial in 150 patients with paroxysmal or persistent AF referred for a first pulmonary vein isolation (PVI). Prior to the ablation, patients in the intervention group receive a personalized risk factor treatment programme in a specialized, protocolized, nurse-led outpatient clinic. Patient education and durable lifestyle management is promoted with an e-health platform. Patients in the control group receive standard care by cardiologists before ablation. The primary endpoint is the number of hospitalizations for re-ablation and cardioversion, with a follow-up of 12 months after ablation. Secondary endpoints include mortality, number of acute ischemic events, stroke or hospitalizations for heart failure, quality of life, number of ablations cancelled because of symptom reduction, and ablation success rate at 12 months. Determinants of patient and staff experience are explored and a cost-effectiveness analysis is included. The POP trial will help ascertain the efficacy and cost-effectiveness of an integrated technology-supported lifestyle therapy in patients with symptomatic AF. The trial is funded by the Netherlands Organisation for Health Research and Development [10070012010001]. Home sleep apnoea testing devices were provided by Itamar Medical, Ltd.ClinicalTrials.gov Identifier NCT05148338. Graphical abstract AF atrial fibrillation, OSA obstructive sleep apnoea, PFA pulsed field ablation, PVI pulmonary vein isolation.Keywords
Funding Information
- ZonMw (10070012010001)
This publication has 39 references indexed in Scilit:
- World Medical Association Declaration of HelsinkiJAMA, 2013
- Treatment of Obstructive Sleep Apnea Reduces the Risk of Atrial Fibrillation Recurrence After Catheter AblationJACC, 2013
- Obesity results in progressive atrial structural and electrical remodeling: Implications for atrial fibrillationHeart Rhythm, 2013
- Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillationEuropean Heart Journal, 2012
- Smoking and incidence of atrial fibrillation: Results from the Atherosclerosis Risk in Communities (ARIC) StudyHeart Rhythm, 2011
- Absolute and Attributable Risks of Atrial Fibrillation in Relation to Optimal and Borderline Risk FactorsCirculation, 2011
- Development and Validation of the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Questionnaire in Patients With Atrial FibrillationCirculation: Arrhythmia and Electrophysiology, 2011
- Catheter Ablation for Atrial FibrillationJACC, 2011
- Physical Activity and Incidence of Atrial Fibrillation in Older AdultsCirculation, 2008
- Obstructive Sleep Apnea, Obesity, and the Risk of Incident Atrial FibrillationJACC, 2007